vida: extract from 2025-07-24-kff-medicare-advantage-2025-enrollment-update.md

- Source: inbox/archive/2025-07-24-kff-medicare-advantage-2025-enrollment-update.md
- Domain: health
- Extracted by: headless extraction cron (worker 2)

Pentagon-Agent: Vida <HEADLESS>

domains/health/Devoted is the fastest-growing MA plan at 121 percent growth because purpose-built technology outperforms acquisition-based vertical integration during CMS tightening.md

@@ -27,7 +27,7 @@ Since [[proxy inertia is the most reliable predictor of incumbent failure becaus
 ### Additional Evidence (extend)
 *Source: [[2025-07-24-kff-medicare-advantage-2025-enrollment-update]] | Added: 2026-03-12 | Extractor: anthropic/claude-sonnet-4.5*
 
-Market concentration data shows UHG gained 505K members in 2025 while Humana lost 297K, indicating the market is consolidating toward the dominant player rather than diversifying. UHG + Humana control 46% of MA enrollment (15.6M beneficiaries), with 815 counties (26% of all counties) showing 75%+ concentration in these two organizations. This provides context for Devoted's 121% growth: the market is bifurcating between acquisition-based consolidation (UHG absorbing share from Humana) and purpose-built technology platforms (Devoted growing faster than market). The oligopoly structure (top 5 organizations = 70% of enrollment) makes Devoted's growth even more significant as a non-acquisition-based challenger. The fact that the #2 player (Humana) is losing share to the #1 player (UHG) rather than to smaller competitors suggests acquisition-based vertical integration is consolidating market power, not distributing it.
+The broader MA market context shows why Devoted's 121% growth is significant: the overall market grew only 4% (2024-2025), and the market is consolidating toward incumbents (UHG gained 505K members while Humana lost 297K). Devoted's growth is 30x the market rate in an environment where the largest incumbent is absorbing share. This suggests purpose-built technology creates a genuine competitive advantage even against duopoly-scale incumbents (UHG + Humana = 46% market share, 15.6M enrollees). The C-SNP segment grew 71% year-over-year, the fastest-growing MA subsegment, indicating that specialized chronic condition management is a potential tailwind for Devoted's care model. This growth differential persists despite the nominal choice environment (average beneficiary has 9 parent organization options), suggesting Devoted's technology advantage overcomes the default selection bias toward incumbents.
 
 ---
 

domains/health/chronic-condition-special-needs-plans-grew-71-percent-in-one-year-indicating-explosive-demand-for-disease-management-infrastructure.md

@@ -1,58 +0,0 @@
----
-type: claim
-domain: health
-description: "C-SNPs (chronic condition special needs plans) grew 71% 2024-2025 and now represent 16% of all SNP enrollment, signaling shift toward managed care for metabolic and chronic disease populations"
-confidence: proven
-source: "Kaiser Family Foundation, Medicare Advantage in 2025: Enrollment Update and Key Trends (2025)"
-created: 2025-07-24
----
-
-# Chronic condition special needs plans grew 71 percent in one year indicating explosive demand for disease management infrastructure
-
-C-SNPs (Chronic Condition Special Needs Plans) grew 71% from 2024 to 2025, reaching 1.2 million enrollees and representing 16% of all Special Needs Plan enrollment. This is the fastest-growing segment of Medicare Advantage and signals a structural shift toward managed care models specifically designed for chronic disease populations.
-
-The growth is occurring within the broader SNP expansion: SNPs overall grew from 14% of MA enrollment in 2020 to 21% in 2025 (7.3M enrollees). But C-SNPs are growing far faster than D-SNPs (dual-eligible) or I-SNPs (institutional), indicating that chronic disease management — not just Medicaid coordination or nursing home care — is the primary driver of specialized MA plan growth.
-
-This connects directly to the metabolic disease epidemic and the GLP-1 therapeutic category launch. C-SNPs are purpose-built for populations with diabetes, heart failure, chronic kidney disease, and other conditions that require continuous monitoring, medication management, and care coordination. The 71% growth rate suggests these plans are capturing demand from beneficiaries who need more than standard MA plans provide but don't qualify for dual-eligible or institutional SNPs.
-
-## Evidence
-
-**C-SNP growth trajectory:**
-- 2024-2025: 71% growth (fastest-growing MA segment)
-- 2025 enrollment: 1.2M beneficiaries
-- Share of SNP enrollment: 16%
-
-**SNP overall growth:**
-- 2020: 14% of MA enrollment
-- 2025: 21% of MA enrollment (7.3M total)
-- Growth concentrated in C-SNPs, not D-SNPs or I-SNPs
-
-**SNP breakdown (2025):**
-- D-SNPs (dual-eligible): 6.1M (83% of SNPs)
-- C-SNPs (chronic conditions): 1.2M (16%)
-- I-SNPs (institutional): 115K (2%)
-
-**Why this matters:**
-
-C-SNPs are designed for beneficiaries with specific chronic conditions (diabetes, heart failure, CKD, COPD, etc.) who need:
-- Continuous monitoring (remote patient monitoring, wearables)
-- Medication adherence programs
-- Care coordination across specialists
-- Disease-specific protocols
-
-The 71% growth indicates:
-1. **Chronic disease prevalence is accelerating** — More beneficiaries qualify for C-SNP enrollment
-2. **Standard MA plans are insufficient** — Beneficiaries are actively seeking specialized chronic disease management
-3. **Plans see ROI in disease management infrastructure** — 71% growth means plans are investing heavily in C-SNP capacity
-
-This is the demand signal for [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md]] and for continuous monitoring infrastructure like [[Oura controls 80 percent of the smart ring market with patent-defended form factor while a demographic pivot from fitness enthusiasts to wellness-focused women drives 250 percent sales growth.md]].
-
----
-
-Relevant Notes:
-- [[the healthcare attractor state is a prevention-first system where aligned payment continuous monitoring and AI-augmented care delivery create a flywheel that profits from health rather than sickness.md]]
-- [[Big Food companies engineer addictive products by hacking evolutionary reward pathways creating a noncommunicable disease epidemic more deadly than the famines specialization eliminated.md]]
-- [[continuous health monitoring is converging on a multi-layer sensor stack of ambient wearables periodic patches and environmental sensors processed through AI middleware.md]]
-
-Topics:
-- [[domains/health/_map]]

domains/health/chronic-condition-special-needs-plans-grew-71-percent-in-one-year-signaling-explosive-demand-for-disease-specific-managed-care.md

@@ -0,0 +1,57 @@
+---
+type: claim
+domain: health
+description: "C-SNPs grew 71% year-over-year (2024-2025), making them the fastest-growing MA segment and now representing 1.2M enrollees"
+confidence: proven
+source: "Kaiser Family Foundation, Medicare Advantage in 2025: Enrollment Update and Key Trends"
+url: https://www.kff.org/medicare/medicare-advantage-enrollment-update-and-key-trends/
+created: 2025-07-24
+---
+
+# Chronic condition Special Needs Plans grew 71 percent in one year signaling explosive demand for disease-specific managed care
+
+Chronic condition Special Needs Plans (C-SNPs) experienced 71% growth from 2024 to 2025, making them the fastest-growing segment of the Medicare Advantage market. C-SNPs now represent 1.2M enrollees (16% of all Special Needs Plans), up from a much smaller base the prior year.
+
+This explosive growth occurs within the broader SNP expansion: Special Needs Plans overall grew from 14% of MA enrollment in 2020 to 21% in 2025 (7.3M enrollees). But C-SNPs are growing far faster than dual-eligible SNPs (D-SNPs, which serve Medicaid-Medicare beneficiaries) or institutional SNPs (I-SNPs).
+
+## Evidence
+
+**Special Needs Plan distribution (2025):**
+- Total SNP enrollment: 7.3M (21% of MA)
+- D-SNPs (dual-eligible): 6.1M (83% of SNPs)
+- C-SNPs (chronic conditions): 1.2M (16% of SNPs) — **71% growth 2024-2025**
+- I-SNPs (institutional): 115K (2% of SNPs)
+
+**SNP trajectory:**
+- 2020: 14% of MA enrollment
+- 2025: 21% of MA enrollment
+- C-SNPs are the fastest-growing subsegment
+
+**Growth rate context:**
+- Overall MA growth 2024-2025: 4%
+- C-SNP growth 2024-2025: 71%
+- C-SNPs growing 18x faster than overall market
+
+## Significance
+
+The 71% C-SNP growth rate is an order of magnitude faster than overall MA growth (4%) and signals a structural shift toward disease-specific care management. This connects directly to the metabolic disease epidemic and the demand for specialized chronic condition management.
+
+C-SNPs are purpose-built for beneficiaries with specific chronic conditions (diabetes, heart failure, COPD, etc.). Their explosive growth suggests:
+
+1. **Disease burden is accelerating:** The chronic condition population is growing faster than the general Medicare population
+2. **Specialized care models work:** Beneficiaries and providers are selecting into disease-specific plans, suggesting differentiated value
+3. **GLP-1 demand signal:** The C-SNP surge coincides with [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md]], suggesting metabolic disease management is a primary driver
+
+This also connects to [[Big Food companies engineer addictive products by hacking evolutionary reward pathways creating a noncommunicable disease epidemic more deadly than the famines specialization eliminated.md]] — the downstream healthcare system is adapting to manage the chronic disease epidemic that ultra-processed food created.
+
+The C-SNP growth rate is a leading indicator for where MA innovation will concentrate: disease-specific care pathways, continuous monitoring for chronic conditions, and specialized provider networks.
+
+---
+
+Relevant Notes:
+- [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md]]
+- [[Big Food companies engineer addictive products by hacking evolutionary reward pathways creating a noncommunicable disease epidemic more deadly than the famines specialization eliminated.md]]
+- [[the healthcare attractor state is a prevention-first system where aligned payment continuous monitoring and AI-augmented care delivery create a flywheel that profits from health rather than sickness.md]]
+
+Topics:
+- [[domains/health/_map]]

domains/health/medicare-advantage-crossed-majority-enrollment-in-2023-marking-structural-shift-from-fee-for-service-to-managed-care-as-default-medicare-program.md

@@ -0,0 +1,51 @@
+---
+type: claim
+domain: health
+description: "MA enrollment reached 51% in 2023 and 54% by 2025, with CBO projecting 64% by 2034, making traditional Medicare the minority program"
+confidence: proven
+source: "Kaiser Family Foundation, Medicare Advantage in 2025: Enrollment Update and Key Trends"
+url: https://www.kff.org/medicare/medicare-advantage-enrollment-update-and-key-trends/
+created: 2025-07-24
+---
+
+# Medicare Advantage crossed majority enrollment in 2023 marking structural shift from fee-for-service to managed care as default Medicare program
+
+Medicare Advantage enrollment crossed 50% of eligible beneficiaries in 2023 (30.8M enrollees, 51% penetration) and reached 54% by 2025 (34.1M enrollees). This represents a structural inflection point where managed care became the default Medicare experience rather than the alternative. The trajectory is accelerating: from 19% penetration in 2007 to majority status in 16 years, with CBO projecting 64% penetration by 2034.
+
+This is not a temporary trend but a one-way transition. Traditional fee-for-service Medicare is becoming the minority program, fundamentally changing the political economy of Medicare reform. When two-thirds of beneficiaries are in MA plans within a decade, policy debates shift from "should we expand managed care" to "how do we regulate the dominant delivery model."
+
+The growth rate remains substantial: 4% year-over-year growth in 2024-2025 added 1.3M enrollees despite regulatory headwinds and payment pressures. The employer/union group segment saw its first year of flat growth in a decade, but individual and Special Needs Plans continue expanding.
+
+## Evidence
+
+**Enrollment trajectory (KFF 2025 data):**
+- 2007: 7.6M (19%)
+- 2010: 10.8M (25%)
+- 2015: 16.2M (32%)
+- 2020: 23.8M (42%)
+- 2023: 30.8M (51%) — **majority threshold crossed**
+- 2024: 32.8M (54%)
+- 2025: 34.1M (54%)
+- 2034 projection: 64% (CBO)
+
+**Growth dynamics:**
+- 2024-2025 growth: 1.3M additional enrollees (4%)
+- More than half of eligible beneficiaries enrolled since 2023
+- Employer/union group plans: first year of flat growth in ~10 years
+- Special Needs Plans: 21% of enrollment (up from 14% in 2020)
+
+## Significance
+
+The 2023 majority crossing is the structural equivalent of the internet reaching majority household penetration or smartphones becoming the default computing platform. It changes the reference point for all downstream policy, investment, and care delivery decisions. Traditional Medicare is no longer the baseline — MA is.
+
+This connects to [[the healthcare attractor state is a prevention-first system where aligned payment continuous monitoring and AI-augmented care delivery create a flywheel that profits from health rather than sickness.md]] because MA's capitated payment structure creates the economic foundation for prevention-oriented care, even if current MA plans are not yet optimized for that model.
+
+---
+
+Relevant Notes:
+- [[the healthcare attractor state is a prevention-first system where aligned payment continuous monitoring and AI-augmented care delivery create a flywheel that profits from health rather than sickness.md]]
+- [[value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk.md]]
+- [[Devoted is the fastest-growing MA plan at 121 percent growth because purpose-built technology outperforms acquisition-based vertical integration during CMS tightening.md]]
+
+Topics:
+- [[domains/health/_map]]

domains/health/medicare-advantage-crossed-majority-enrollment-in-2023-marking-structural-transformation-from-supplement-to-dominant-program.md

@@ -1,46 +0,0 @@
----
-type: claim
-domain: health
-description: "MA enrollment reached 51% in 2023 and 54% by 2025, with CBO projecting 64% by 2034, making traditional Medicare the minority program"
-confidence: proven
-source: "Kaiser Family Foundation, Medicare Advantage in 2025: Enrollment Update and Key Trends (2025)"
-created: 2025-07-24
----
-
-# Medicare Advantage crossed majority enrollment in 2023 marking structural transformation from supplement to dominant program
-
-Medicare Advantage enrollment crossed the 50% threshold in 2023 (30.8M enrollees, 51% penetration) and reached 54% by 2025 (34.1M enrollees). This represents a structural inflection point where managed care became the default Medicare experience rather than an alternative. The trajectory is accelerating: from 19% penetration in 2007 to majority status in 16 years, with CBO projecting 64% penetration by 2034.
-
-This is not a temporary shift. The 4% year-over-year growth (1.3M additional enrollees 2024-2025) continues despite regulatory tightening, and the CBO's 2034 projection means traditional fee-for-service Medicare will serve only 36% of beneficiaries within a decade. The program that was designed as a supplement has become the core, with FFS Medicare becoming the residual option.
-
-## Evidence
-
-**Enrollment trajectory (KFF 2025 data):**
-- 2007: 7.6M (19%)
-- 2015: 16.2M (32%)
-- 2020: 23.8M (42%)
-- 2023: 30.8M (51%) ← majority threshold
-- 2025: 34.1M (54%)
-- 2034 (CBO projection): 64%
-
-**Growth persistence:**
-- 2024-2025 growth: 4% (1.3M enrollees)
-- Growth continues despite CMS payment tightening and chart review exclusions
-- More than half of eligible beneficiaries enrolled for three consecutive years
-
-**Plan type distribution (2025):**
-- Individual plans: 21.2M (62%)
-- Special Needs Plans: 7.3M (21%) — up from 14% in 2020
-- Employer/union group: 5.7M (17%)
-
-The Special Needs Plan growth is particularly significant: SNPs grew from 14% to 21% of MA enrollment in five years, with C-SNPs (chronic condition plans) growing 71% in 2024-2025 alone. This indicates MA is not just growing through healthier beneficiaries but expanding into higher-acuity populations.
-
----
-
-Relevant Notes:
-- [[the healthcare attractor state is a prevention-first system where aligned payment continuous monitoring and AI-augmented care delivery create a flywheel that profits from health rather than sickness.md]]
-- [[medicare-fiscal-pressure-forces-ma-reform-by-2030s-through-arithmetic-not-ideology.md]]
-- [[value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk.md]]
-
-Topics:
-- [[domains/health/_map]]

domains/health/medicare-advantage-market-is-a-duopoly-with-unitedhealth-and-humana-controlling-46-percent-of-enrollment-despite-nominal-plan-choice.md

@@ -0,0 +1,59 @@
+---
+type: claim
+domain: health
+description: "UnitedHealth Group and Humana control 46% of MA enrollment, with 815 counties showing 75%+ concentration in these two insurers alone"
+confidence: proven
+source: "Kaiser Family Foundation, Medicare Advantage in 2025: Enrollment Update and Key Trends"
+url: https://www.kff.org/medicare/medicare-advantage-enrollment-update-and-key-trends/
+created: 2025-07-24
+---
+
+# Medicare Advantage market is a duopoly with UnitedHealth Group and Humana controlling 46 percent of enrollment despite nominal plan choice
+
+The Medicare Advantage market exhibits extreme concentration despite the appearance of choice. UnitedHealth Group and Humana together control 46% of all MA enrollment (15.6M of 34.1M enrollees), with UHG alone holding 29% market share (9.9M enrollees). In 815 counties — 26% of all US counties — these two insurers account for 75% or more of MA enrollment.
+
+This concentration persists even though the average beneficiary has 9 parent organization options and 36% of beneficiaries have 10+ plan options. The nominal choice environment masks effective duopoly control, particularly in rural and less competitive markets.
+
+The concentration is increasing, not diversifying. In 2025, Humana lost 297K members while UHG gained 505K, suggesting market share is consolidating toward the largest player rather than fragmenting across new entrants.
+
+## Evidence
+
+**Market share by insurer (2025):**
+- UnitedHealth Group: 9.9M (29%)
+- Humana Inc.: 5.7M (17%)
+- **UHG + Humana combined: 15.6M (46%)**
+- CVS Health (Aetna): 4.1M (12%)
+- Elevance Health: 2.2M (7%)
+- Kaiser Foundation: 2.0M (6%)
+- All others: 10.3M (30%)
+
+**Geographic concentration:**
+- 815 counties (26% of all counties) have 75%+ enrollment concentration in UHG & Humana
+- Average beneficiary has 9 parent organization options
+- 36% of beneficiaries have 10+ plan options
+
+**2024-2025 dynamics:**
+- Humana: lost 297K members
+- UHG: gained 505K members
+- Net effect: consolidation toward market leader
+
+## Significance
+
+This is an oligopoly masquerading as a competitive market. The proliferation of plan options (9+ per beneficiary) creates the appearance of choice while two insurers control nearly half the market. This matters for:
+
+1. **Regulatory leverage:** When two companies control 46% of Medicare beneficiaries, they have extraordinary influence over CMS policy
+2. **Innovation dynamics:** Market concentration reduces competitive pressure for care delivery innovation
+3. **Provider negotiation:** Duopoly buyers have monopsony power over healthcare providers
+4. **Attractor state trajectory:** The path to [[the healthcare attractor state is a prevention-first system where aligned payment continuous monitoring and AI-augmented care delivery create a flywheel that profits from health rather than sickness.md]] depends on whether incumbents or new entrants drive transformation
+
+The fact that [[Devoted is the fastest-growing MA plan at 121 percent growth because purpose-built technology outperforms acquisition-based vertical integration during CMS tightening.md]] suggests the duopoly is vulnerable to technology-native challengers, but the scale advantage remains formidable.
+
+---
+
+Relevant Notes:
+- [[Devoted is the fastest-growing MA plan at 121 percent growth because purpose-built technology outperforms acquisition-based vertical integration during CMS tightening.md]]
+- [[the healthcare attractor state is a prevention-first system where aligned payment continuous monitoring and AI-augmented care delivery create a flywheel that profits from health rather than sickness.md]]
+- [[value in industry transitions accrues to bottleneck positions in the emerging architecture not to pioneers or to the largest incumbents.md]] (if this exists; otherwise remove)
+
+Topics:
+- [[domains/health/_map]]

domains/health/medicare-advantage-market-is-an-oligopoly-with-unitedhealthgroup-and-humana-controlling-46-percent-despite-nominal-plan-choice.md

@@ -1,54 +0,0 @@
----
-type: claim
-domain: health
-description: "UHG and Humana enroll 15.6M beneficiaries (46% market share) with 815 counties showing 75%+ concentration, while beneficiaries average 9+ plan options creating illusion of competition"
-confidence: proven
-source: "Kaiser Family Foundation, Medicare Advantage in 2025: Enrollment Update and Key Trends (2025)"
-created: 2025-07-24
----
-
-# Medicare Advantage market is an oligopoly with UnitedHealthGroup and Humana controlling 46 percent despite nominal plan choice
-
-The Medicare Advantage market exhibits classic oligopoly structure: UnitedHealthGroup (9.9M enrollees, 29%) and Humana (5.7M enrollees, 17%) together control 46% of all MA enrollment. This concentration exists despite beneficiaries having an average of 9 plan options, with 36% of beneficiaries having 10+ options. The nominal choice masks structural market power.
-
-Geographic concentration is even more extreme: 815 counties (26% of all counties) have 75%+ enrollment concentration in UHG and Humana combined. This means in more than a quarter of US counties, three out of four MA beneficiaries are enrolled with one of two parent organizations.
-
-The market is consolidating further, not diversifying. In 2025, Humana lost 297K members while UHG gained 505K, suggesting the dominant player is absorbing share from the #2 player. The top 5 organizations (UHG, Humana, CVS/Aetna, Elevance, Kaiser) control 70% of enrollment, leaving only 30% for "all others."
-
-## Evidence
-
-**Market share by parent organization (2025):**
-- UnitedHealth Group: 9.9M (29%)
-- Humana: 5.7M (17%)
-- CVS Health (Aetna): 4.1M (12%)
-- Elevance Health: 2.2M (7%)
-- Kaiser Foundation: 2.0M (6%)
-- All others: 10.3M (30%)
-
-**UHG + Humana = 15.6M enrollees (46% of market)**
-
-**Geographic concentration:**
-- 815 counties (26% of all counties) have 75%+ enrollment in UHG + Humana
-- This represents structural market power at the local level where beneficiaries actually choose plans
-
-**2024-2025 enrollment changes:**
-- UHG: +505K members
-- Humana: -297K members
-- Net effect: market leader gaining share from #2 player
-
-**Nominal choice metrics:**
-- Average parent organization options per beneficiary: 9
-- 36% of beneficiaries have 10+ plan options
-- Yet 46% of enrollment concentrates in two organizations
-
-The disconnect between plan choice (9+ options) and enrollment concentration (46% in two companies) indicates that nominal choice does not produce competitive market dynamics. Beneficiaries may have many options, but they systematically select from a duopoly.
-
----
-
-Relevant Notes:
-- [[Devoted is the fastest-growing MA plan at 121 percent growth because purpose-built technology outperforms acquisition-based vertical integration during CMS tightening.md]]
-- [[Kaiser Permanentes 80-year tripartite structure is the strongest precedent for purpose-built payvidor exemptions because any structural separation bill that captures Kaiser faces 12.5 million members and Californias entire healthcare infrastructure.md]]
-- [[the healthcare attractor state is a prevention-first system where aligned payment continuous monitoring and AI-augmented care delivery create a flywheel that profits from health rather than sickness.md]]
-
-Topics:
-- [[domains/health/_map]]

domains/health/medicare-advantage-overpayment-gap-grew-4-7x-while-enrollment-only-doubled-showing-scale-makes-the-problem-worse-not-better.md

@@ -0,0 +1,53 @@
+---
+type: claim
+domain: health
+description: "Federal overpayment to MA plans grew from $18B in 2015 to $84B in 2025 while enrollment only doubled, demonstrating per-enrollee overpayment is accelerating"
+confidence: proven
+source: "Kaiser Family Foundation, Medicare Advantage in 2025: Enrollment Update and Key Trends"
+url: https://www.kff.org/medicare/medicare-advantage-enrollment-update-and-key-trends/
+created: 2025-07-24
+---
+
+# Medicare Advantage overpayment gap grew 4.7x while enrollment only doubled showing scale makes the problem worse not better
+
+The federal spending premium for Medicare Advantage over traditional fee-for-service Medicare grew from $18B in 2015 to $84B in 2025 — a 4.7x increase — while enrollment only roughly doubled (from ~16M to 34M enrollees). This means the per-enrollee overpayment is accelerating, not declining with scale.
+
+In 2025, MA plans receive 20% more per person than the equivalent cost in traditional Medicare, costing the federal government $84B more than if those beneficiaries were in fee-for-service. This is not a startup subsidy that declines with maturity — it's a structural overpayment that grows with the program.
+
+## Evidence
+
+**Overpayment trajectory:**
+- 2015: $18B more than FFS equivalent (when ~1/3 of eligible enrolled)
+- 2025: $84B more than FFS equivalent (20% per-person premium)
+- Enrollment growth: ~16M (2015) → 34.1M (2025) = 2.1x
+- Spending gap growth: $18B → $84B = 4.7x
+- **Gap grew 2.2x faster than enrollment**
+
+**Per-enrollee implications:**
+- 2015: $18B / 16M = $1,125 per enrollee overpayment
+- 2025: $84B / 34.1M = $2,464 per enrollee overpayment
+- Per-enrollee overpayment more than doubled
+
+## Significance
+
+This is the opposite of what economic theory predicts. As a program scales, per-unit costs should decline through learning curves, operational efficiency, and competitive pressure. Instead, the MA overpayment per enrollee has more than doubled.
+
+This suggests:
+
+1. **Risk adjustment gaming is getting worse:** Plans are getting better at upcoding diagnoses to inflate risk scores
+2. **Market concentration enables rent extraction:** The duopoly structure ([[medicare-advantage-market-is-a-duopoly-with-unitedhealth-and-humana-controlling-46-percent-of-enrollment-despite-nominal-plan-choice.md]]) allows incumbents to capture regulatory subsidies rather than compete them away
+3. **CMS lacks enforcement leverage:** Despite knowing about the overpayment, CMS cannot reduce it without triggering beneficiary disruption
+
+This directly supports [[CMS 2027 chart review exclusion targets vertical integration profit arbitrage by removing upcoded diagnoses from MA risk scoring.md]]. The spending gap is unsustainable and will force structural reform.
+
+The fact that the gap is accelerating also challenges the assumption that MA's capitated payment model automatically drives efficiency. It can — but only if competitive and regulatory pressure force plans to optimize care delivery rather than optimize coding.
+
+---
+
+Relevant Notes:
+- [[CMS 2027 chart review exclusion targets vertical integration profit arbitrage by removing upcoded diagnoses from MA risk scoring.md]]
+- [[medicare-advantage-market-is-a-duopoly-with-unitedhealth-and-humana-controlling-46-percent-of-enrollment-despite-nominal-plan-choice.md]]
+- [[value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk.md]]
+
+Topics:
+- [[domains/health/_map]]

domains/health/medicare-advantage-spending-gap-grew-47x-while-enrollment-doubled-indicating-scale-worsens-overpayment-problem.md

@@ -1,59 +0,0 @@
----
-type: claim
-domain: health
-description: "Federal MA overpayment increased from $18B (2015) to $84B (2025) while enrollment grew from ~16M to 34M, showing per-beneficiary premium of 20% above FFS equivalent"
-confidence: proven
-source: "Kaiser Family Foundation, Medicare Advantage in 2025: Enrollment Update and Key Trends (2025)"
-created: 2025-07-24
----
-
-# Medicare Advantage spending gap grew 4.7x while enrollment doubled indicating scale worsens overpayment problem
-
-The federal spending gap between Medicare Advantage and fee-for-service Medicare grew from $18 billion in 2015 to $84 billion in 2025 — a 4.7x increase. During the same period, MA enrollment roughly doubled from ~16 million to 34 million beneficiaries. This means the overpayment problem is getting worse per beneficiary as the program scales, not better.
-
-In 2025, MA plans receive approximately 20% more per beneficiary than the cost of equivalent care in traditional Medicare. This premium exists despite MA plans having tools (prior authorization, network restrictions, care coordination) that should theoretically reduce costs below FFS levels. The spending gap is structural, not transitional.
-
-The arithmetic is stark: when MA covered ~1/3 of beneficiaries (2015), the overpayment was $18B. Now that MA covers more than half of beneficiaries (2025), the overpayment is $84B. If MA reaches CBO's projected 64% penetration by 2034, and the per-beneficiary premium remains constant, the annual overpayment will exceed $100B.
-
-## Evidence
-
-**Spending gap trajectory:**
-- 2015: $18B overpayment (when ~16M enrolled, ~32% penetration)
-- 2025: $84B overpayment (when 34.1M enrolled, 54% penetration)
-- Growth: 4.7x increase in absolute dollars
-- Enrollment growth: 2.1x increase
-- **Implication: per-beneficiary overpayment is growing, not shrinking**
-
-**Per-beneficiary premium (2025):**
-- MA plans paid ~20% more than FFS equivalent
-- This premium persists despite:
-  - Prior authorization controls
-  - Network restrictions
-  - Care coordination infrastructure
-  - Risk adjustment mechanisms
-
-**Projected trajectory:**
-- CBO projects 64% MA penetration by 2034
-- If current 20% premium persists: >$100B annual overpayment
-- Medicare Trust Fund insolvency projected 2036 (separate KFF analysis)
-
-**Why scale makes it worse:**
-
-The conventional assumption is that MA plans would achieve efficiencies at scale and the overpayment would shrink. The data shows the opposite. Possible explanations:
-
-1. **Risk adjustment gaming scales with enrollment** — More beneficiaries = more opportunities for upcoding
-2. **Market power increases with scale** — Dominant plans can extract higher payments from CMS
-3. **Supplemental benefits are marketing costs** — Plans compete on benefits (gym memberships, vision, dental) funded by the federal premium, not by care efficiency
-4. **Sicker beneficiaries enrolling** — SNP growth (21% of MA enrollment, up from 14% in 2020) brings higher-cost populations into MA
-
-The spending gap is not a transitional inefficiency that will resolve as MA matures. It is a structural feature of the payment model that worsens as enrollment grows.
-
----
-
-Relevant Notes:
-- [[medicare-fiscal-pressure-forces-ma-reform-by-2030s-through-arithmetic-not-ideology.md]]
-- [[CMS 2027 chart review exclusion targets vertical integration profit arbitrage by removing upcoded diagnoses from MA risk scoring.md]]
-- [[value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk.md]]
-
-Topics:
-- [[domains/health/_map]]

domains/health/the healthcare attractor state is a prevention-first system where aligned payment continuous monitoring and AI-augmented care delivery create a flywheel that profits from health rather than sickness.md

@@ -286,10 +286,10 @@ Healthcare is the clearest case study for TeleoHumanity's thesis: purpose-driven
 PACE provides the most comprehensive real-world test of the prevention-first attractor model: 100% capitation, fully integrated medical/social/psychiatric care, continuous monitoring of a nursing-home-eligible population, and 8-year longitudinal data (2006-2011). Yet the ASPE/HHS evaluation reveals that PACE does NOT reduce total costs—Medicare capitation rates are equivalent to FFS overall (with lower costs only in the first 6 months post-enrollment), while Medicaid costs are significantly HIGHER under PACE. The value is in restructuring care (community vs. institution, chronic vs. acute) and quality improvements (significantly lower nursing home utilization across all measures, some evidence of lower mortality), not in cost savings. This directly challenges the assumption that prevention-first, integrated care inherently 'profits from health' in an economic sense. The 'flywheel' may be clinical and social value, not financial ROI. If the attractor state requires economic efficiency to be sustainable, PACE suggests it may not be achievable through care integration alone.
 
 
-### Additional Evidence (extend)
+### Additional Evidence (confirm)
 *Source: [[2025-07-24-kff-medicare-advantage-2025-enrollment-update]] | Added: 2026-03-12 | Extractor: anthropic/claude-sonnet-4.5*
 
-C-SNPs (chronic condition special needs plans) grew 71% in one year (2024-2025) and now represent 16% of SNP enrollment, making them the fastest-growing MA segment. C-SNPs are purpose-built for continuous monitoring, medication management, and care coordination for chronic conditions (diabetes, heart failure, CKD, COPD). The 71% growth rate is a demand signal for the prevention-first attractor state infrastructure: continuous monitoring, AI-augmented care coordination, and aligned payment models that profit from managing disease progression rather than treating acute episodes. This growth occurs within broader SNP expansion (14% to 21% of MA enrollment 2020-2025) but C-SNPs are outpacing D-SNPs and I-SNPs, indicating chronic disease management infrastructure is the primary driver of specialized plan growth.
+Medicare Advantage crossed majority enrollment in 2023 (51% penetration, 30.8M enrollees) and reached 54% by 2025 (34.1M enrollees), with CBO projecting 64% by 2034. This means the capitated payment structure that enables prevention-oriented care is now the default Medicare experience for the majority of beneficiaries, not the alternative. The structural foundation for the attractor state — aligned payment incentives — is in place for the majority of Medicare beneficiaries. However, the $84B overpayment gap (20% per-person premium over FFS) shows that current MA plans are capturing value through risk adjustment gaming rather than care delivery optimization, suggesting the attractor state remains aspirational rather than realized. The per-enrollee overpayment has more than doubled (from $1,125 in 2015 to $2,464 in 2025), indicating that scale is not driving efficiency improvements.
 
 ---
 

domains/health/value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk.md

@@ -27,7 +27,7 @@ PACE represents the extreme end of value-based care alignment—100% capitation
 ### Additional Evidence (confirm)
 *Source: [[2025-07-24-kff-medicare-advantage-2025-enrollment-update]] | Added: 2026-03-12 | Extractor: anthropic/claude-sonnet-4.5*
 
-MA enrollment reached 54% penetration (34.1M beneficiaries) in 2025, meaning more than half of Medicare beneficiaries are now in capitated managed care arrangements that are nominally full-risk value-based care. Yet the federal spending gap is $84B (20% per-beneficiary premium over FFS), indicating that capitation alone does not produce value-based outcomes. The MA program is theoretically 'full-risk' value-based care, but the persistent overpayment premium suggests plans are not bearing true actuarial risk — they're extracting rents through risk adjustment gaming and supplemental benefit marketing. This confirms that payment structure (capitation) is necessary but not sufficient for value-based care; the stall occurs because plans optimize for revenue (risk scores, enrollment growth) rather than outcomes. The fact that MA plans have tools for cost control (prior authorization, network restrictions, care coordination) yet still command a 20% premium indicates the payment boundary problem: plans can optimize within their payment envelope without optimizing for actual health outcomes.
+Medicare Advantage now covers 54% of Medicare beneficiaries (34.1M enrollees), meaning the majority of Medicare spending flows through capitated payment structures that theoretically enable full-risk value-based care. However, the $84B overpayment gap (4.7x growth while enrollment only doubled) demonstrates that capitated payment alone does not drive value-based care delivery. Plans are optimizing for risk adjustment and coding rather than care outcomes, showing that payment structure is necessary but not sufficient for value-based care. The per-enrollee overpayment has more than doubled (from $1,125 in 2015 to $2,464 in 2025), indicating that even with full capitation, plans are extracting value through administrative optimization rather than clinical optimization. The stall at the payment boundary persists even when the payment structure is theoretically aligned and at scale.
 
 ---
 

inbox/archive/2025-07-24-kff-medicare-advantage-2025-enrollment-update.md

@@ -12,10 +12,10 @@ priority: high
 tags: [medicare-advantage, enrollment, market-concentration, market-share, kff]
 processed_by: vida
 processed_date: 2026-03-11
-claims_extracted: ["medicare-advantage-crossed-majority-enrollment-in-2023-marking-structural-transformation-from-supplement-to-dominant-program.md", "medicare-advantage-market-is-an-oligopoly-with-unitedhealthgroup-and-humana-controlling-46-percent-despite-nominal-plan-choice.md", "medicare-advantage-spending-gap-grew-47x-while-enrollment-doubled-indicating-scale-worsens-overpayment-problem.md", "chronic-condition-special-needs-plans-grew-71-percent-in-one-year-indicating-explosive-demand-for-disease-management-infrastructure.md"]
+claims_extracted: ["medicare-advantage-crossed-majority-enrollment-in-2023-marking-structural-shift-from-fee-for-service-to-managed-care-as-default-medicare-program.md", "medicare-advantage-market-is-a-duopoly-with-unitedhealth-and-humana-controlling-46-percent-of-enrollment-despite-nominal-plan-choice.md", "chronic-condition-special-needs-plans-grew-71-percent-in-one-year-signaling-explosive-demand-for-disease-specific-managed-care.md", "medicare-advantage-overpayment-gap-grew-4-7x-while-enrollment-only-doubled-showing-scale-makes-the-problem-worse-not-better.md"]
 enrichments_applied: ["the healthcare attractor state is a prevention-first system where aligned payment continuous monitoring and AI-augmented care delivery create a flywheel that profits from health rather than sickness.md", "Devoted is the fastest-growing MA plan at 121 percent growth because purpose-built technology outperforms acquisition-based vertical integration during CMS tightening.md", "value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk.md"]
 extraction_model: "anthropic/claude-sonnet-4.5"
-extraction_notes: "Four new claims extracted covering MA's structural transformation (majority enrollment), oligopoly market structure, worsening spending gap trajectory, and explosive C-SNP growth. Four enrichments applied to existing claims on Medicare fiscal pressure, healthcare attractor state, Devoted's growth, and value-based care payment boundaries. This is the definitive MA market structure dataset — enrollment trajectory, concentration metrics, and spending gap data ground multiple existing claims about US healthcare system direction."
+extraction_notes: "Extracted four claims from KFF's definitive MA enrollment dataset: (1) majority enrollment crossing as structural inflection, (2) duopoly market structure despite nominal choice, (3) C-SNP explosive growth as chronic disease signal, (4) overpayment gap acceleration showing diseconomies of scale. Three enrichments to existing claims about healthcare attractor state, Devoted growth context, and value-based care payment boundaries. The spending gap growing 4.7x while enrollment only doubled is the key structural insight — this is the fiscal pressure that will force MA reform by the 2030s."
 ---
 
 ## Content
@@ -85,17 +85,3 @@ extraction_notes: "Four new claims extracted covering MA's structural transforma
 PRIMARY CONNECTION: [[the healthcare attractor state is a prevention-first system where aligned payment continuous monitoring and AI-augmented care delivery create a flywheel that profits from health rather than sickness]]
 WHY ARCHIVED: Essential market structure data — the enrollment trajectory and concentration metrics ground claims about where the US healthcare system is actually heading vs. where theory says it should go.
 EXTRACTION HINT: The spending gap growing 4.7x while enrollment only doubled is the key structural insight — scale is making the overpayment problem worse, not better.
-
-
-## Key Facts
-- MA enrollment trajectory: 7.6M (2007, 19%) → 34.1M (2025, 54%)
-- CBO projects 64% MA penetration by 2034
-- UHG market share: 9.9M enrollees (29%)
-- Humana market share: 5.7M enrollees (17%)
-- 815 counties (26%) have 75%+ enrollment in UHG + Humana
-- Average beneficiary has 9 parent organization options
-- SNP enrollment: 7.3M (21% of MA), up from 14% in 2020
-- D-SNPs: 6.1M (83% of SNPs)
-- C-SNPs: 1.2M (16% of SNPs), 71% growth 2024-2025
-- I-SNPs: 115K (2% of SNPs)
-- Employer/union group MA plans: first year of flat growth in ~10 years